HUM240719P370000
- 1.29
- -0.54-29.51%
Humana Newsroom
Express News | Truist Securities Maintains Hold on Humana, Raises Price Target to $400
Humana Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 2.7% Truist Securities $355 → $400 Maintains Hold 06/26/2024 0.65% Piper Sandler → $392
Express News | Humana Shares up 3.1%, UnitedHealth up 2.3%, CVS Health up 1.1%
Truist Financial Maintains Humana(HUM.US) With Hold Rating, Raises Target Price to $400
Truist Financial analyst David S Macdonald maintains $Humana(HUM.US)$ with a hold rating, and adjusts the target price from $355 to $400.According to TipRanks data, the analyst has a success rate of 6
Express News | Shares of Several Health Insurance Stocks Are Trading Higher Following the Attempted Assassination of Donald Trump, Which Has Lifted Stocks That Could Benefit From a Trump Presidency on Monday
Trump's Betting Election Odds Surge After Assassination Attempt, How Would The Market React?
On Saturday, Donald Trump was shot at a campaign rally in Pennsylvania, which could be a key moment that completely disrupts the US election landscape this year. Following the incident, data from Polymarket shows that Trump's chances of winning the election have skyrocketed to 71%.
Express News | Humana Shares up 2.3%, UnitedHealth up 2.2%, CVS Health up 1.7%, Cigna up 1.7%
Express News | Health Insurance Stocks Gain Premarket as Odds of Trump Victory Rise After Shooting
Express News | Humana Inc : Truist Securities Raises Target Price to $400 From $355
Concept stocks take off across the board! Trump's company surged more than 70% before the market opened, and Tesla also soared!
I won!
UnitedHealth Earnings Preview: Will the Health Insurance Giant Emerge from Rare Market Turbulences?
Analysts estimate UnitedHealthcare to post revenue of USD 98.8 billion for 2024Q2, up 6.35% YOY; EPS is estimated to be USD 6.28, up 7.89% YOY.
If You Invested $100 In This Stock 20 Years Ago, You Would Have $2,200 Today
Humana (NYSE:HUM) has outperformed the market over the past 20 years by 8.18% on an annualized basis producing an average annual return of 16.6%. Currently, Humana has a market capitalization of $45.7
Express News | Humana Inc : Mizuho Raises Target Price to $410 From $385
Update: US FTC Report Says Pharmacy Benefit Managers Contribute to Higher Drug Costs
(Updates to add comment from United Health's Optum in the seventh paragraph.)CVS Health's (CVS) Caremark, UnitedHealth Group's (UNH) Optum, and Cigna Group's (CI) Express Scripts are among the top
FTC Investigation Uncovers Anti-Competitive Practices By Handful Of Pharmacy Benefit Managers, Including CVS Health, UnitedHealth
The U.S. Federal Trade Commission (FTC) has highlighted significant concerns regarding consolidating pharmacies and health insurance companies, focusing on the influence of a few dominant pharmacy
US FTC Report Says Pharmacy Benefit Managers Contribute to Higher Drug Costs
CVS Health's (CVS) Caremark, UnitedHealth Group's (UNH) Optum, and Cigna Group's (CI) Express Scripts are among the top six pharmacy middlemen that contribute to higher drug costs and challenge the
Pharma Middlemen Benefit at the Expense of Patients: FTC
Here's Why Appleseed Fund Added Humana (HUM) on Dip
USA government unhappy with high drug prices, these three American healthcare giants have become “regulatory targets”.
According to Zhìtōng Cáijīng, the US Federal Trade Commission (FTC) stated on Tuesday that the integration of pharmacies and medical insurance companies after years of mergers has led to a few pharmacy benefit management companies exerting too much influence on prescription drug prices. The antitrust efforts of US regulators has focused on several large pharmacy benefit management companies, with the three largest in the US being Optum of UnitedHealth (UNH.US), CVS Caremark of CVS Health (CVS.US), and Express Scripts of The Cigna Group (CI.US). Pharmaceutical benefits.
RBC Raises Price Target on Humana to $385 From $353, Outperform Rating Kept
Humana (HUM) has an average outperform rating and a price target range of $326 to $473, according to analysts polled by Capital IQ.Price: 368.50, Change: -1.93, Percent Change: -0.52